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Additional file: Table 1. Comparison of indicative times and costs necessary to produce 
monoclonal antibodies 
Calculations have been performed considering already available soluble antigens and material and 
personnel costs as experienced in our lab. In the case of membrane proteins, both time and costs can be 
significantly increased when the antigen must be purified for animal immunization. In contrast, there 
are no longer panning time and further costs for in vitro selection. 
 
 Monoclonal recombinant antibodies 
obtained by panning pre-immune libraries 
Monoclonal antibodies obtained 
by hybridoma technology 
Time (immunization, Ab 
isolation and production) 
1 month 4-6 months 
Costs for Ab isolation 1000 euro 6-8000 euro 
Costs for Ab production 20 euro/mg 1000-2000 euro mg 
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Supplementary Figures 
 
Supplementary Figure 1. Chromatographic separation of kit-purified EV-enriched fraction from 
culture media 
Kit-precipitated EVs present in SKBR3 cell culture supernatant were separated using a large-pore 
anion-exchange monolith column. All the four separated fractions were analyzed by flow-cytometry 
and resulted positive for the EV marker CD9 
Supplementary Figure 2. Purification strategy of VHH-GFP constructs 
H1-GFP and H6-GFP constructs were expressed in E. coli and purified from the soluble fraction using 
immobilized metal-affinity chromatography. The corresponding chromatograms are reported together 
with the SDS-gels of total bacterial lysate (lane 1) and elution fractions 10-12 (lanes 2, 3, 4). After 
desalting, the samples underwent IEX purification and the eluted fractions were separated by SDS-
PAGE (H6, lanes 1-10; H1, lanes 11-19; MW: molecular weight markers) 
 
 
Supplementary Figure 3. Antibody differential binding to cell-derived EVs 
EVs derived from HEK-293, SKBR3, and Jurkat cells were used to evaluate the binding preferences of 
the nanobodies H1 and B1 compared with the binding of the irrelevant clone nbVHH (A-C). The 
binding capacity of a commercial anti-CD9 antibody was tested with the same cell lines (D). Bars 
indicate median percentage of positively stained EV coated beads with anti-CD9–PE antibodies to H1-
GFP, B1-GFP, and non-binding VHH coated beads with respect to autofluorescence of unstained EV 
coated beads. The error bars indicate standard deviations for triplicate measurements 
 
Supplementary Figure 4. Anti-exosome nanobodies bind EV-fractions separated by chromatography 
Flow cytometry experiments show that both H1 and H6 strongly bind to exosomes present in the 
fraction 1 separated by IEX chromatography 
